Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model

about

Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model

Item

http://www.wikidata.org/entity/Q41857036

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Impact of JC virus antibody te ...... to infliximab: a Markov model

@en

type

Item

label

Impact of JC virus antibody te ...... to infliximab: a Markov model

@en

prefLabel

Impact of JC virus antibody te ...... to infliximab: a Markov model

@en

P1476

Impact of JC virus antibody te ...... to infliximab: a Markov model

@en

P2093

Caroline Kerner

http://www.w3.org/2001/XMLSchema#string

Faten Aberra

http://www.w3.org/2001/XMLSchema#string

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Mark T Osterman

http://www.w3.org/2001/XMLSchema#string

Monica Lorusso

http://www.w3.org/2001/XMLSchema#string

Ryan A McConnell

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Natalizumab for induction of remission in Crohn's disease

Natalizumab for active Crohn's disease

Risks and benefits of infliximab for the treatment of Crohn's disease

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

P304

2625-2633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.MIB.0000437043.36338.21

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Frank I. Scott

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24108113

http://www.w3.org/2001/XMLSchema#string

P932

4113592

http://www.w3.org/2001/XMLSchema#string